[1]马兰虎 姚亚丽.射血分数中间范围心力衰竭预后的研究进展[J].心血管病学进展,2022,(2):146.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.013]
　MA Lanhu,YAO Yali.Prognosis in Heart Failure with Mid-Range Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(2):146.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.013]
点击复制

射血分数中间范围心力衰竭预后的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年2期
页码:
146
栏目:
综述
出版日期:
2022-02-25

文章信息/Info

Title:
Prognosis in Heart Failure with Mid-Range Ejection Fraction
作者:
马兰虎1 姚亚丽2
(1.兰州大学第一临床医学院,甘肃 兰州 73000;2.兰州大学第一医院心内科,甘肃 兰州 730000)
Author(s):
MA Lanhu1; YAO Yali2
(1.The First Clinical Medical College of Lanzhou University,Lanzhou 730000,Gansu,China;2.Heart Center,The First Hospital of Lanzhou University,Lanzhou 730000, Gansu,China)
关键词:
射血分数中间范围心力衰竭; 射血分数; 预后
Keywords:
Heart failure with mid-range ejection fraction;  Ejection Fraction;  Prognosis
DOI:
10.16806/j.cnki.issn.1004-3934.2022.02.013
摘要:
射血分数中间范围心力衰竭(HFmrEF)是作为一种特殊类型的心力衰竭表型，处于射血分数降低性心力衰竭（HFrEF）与射血分数保留性心力衰竭(HFpEF)之间的“灰色区域”，目前研究对于HFmrEF是为一个独立的临床综合征还是介于HFrEF和HFpEF之间的“过渡阶段”存在一定争议。现对HFmrEF的流行病学、机制、治疗和预后等方面进行综述，为临床提供有效的治疗策略。
Abstract:
The heart failure with mid-range ejection fraction(HFmrEF) is considered as a special phenotype,which lies in the "gray area" between heart failure with reduced ejection fraction(HF rEF) and heart failure with preserved ejection fraction(HFpEF). The current study is about whether HFmrEF as an independent clinical syndrome,there is some controversy in the "transitional phase" between HFrEF and HFpEF. This paper reveals the epidemiology,mechanism,treatment,and prognosis of patients with HFmrEF,and provides effective treatment strategies for the clinic

参考文献/References:


[1]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志,2018,46(10):760-789.

[2]Lam CSP, Yancy C. Universal definition and classification of heart failure:is it universal?Does it define heart failure?[J]. J Card Fail,2021,27(5):509-511.

[3]Lopatin Y. Heart failur with mid-range ejection fraction and how to treat it[J]. Card Fail Rev,2018,4(1):9-13.

[4]Chioncel O,Lainscak M,Seferovic PM,et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved,mid-range and reduced ejection fraction:an analysis of the ESC Heart Failure Long-Term Registry[J]. Eur J Heart Fail,2017,19(12):1574-1585.

[5]Sartipy U,Dahlstr?m U,Fu M,et al. Atrial fibrillation in heart failure with preserved,mid-range,and reduced ejection fraction[J]. JACC Heart Fail,2017,5(8):565-574.

[6]Savarese G,Vedin O,D’Amario D,et al. Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure[J]. JACC Heart Fail,2019,7(4):306-317.

[7]Follath F,Yilmaz MB,Delgado JF,et al. Clinical presentation,management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF)[J]. Intensive Care Med,2011,37(4):619-626.

[8]Ibrahim NE,Song Y,Cannon CP,et al. Heart failure with mid-range ejection fraction:characterization of patients from the PINNACLE Registry?[J]. ESC Heart Fail,2019,6(4):784-792.

[9]Shah KS,Xu H,Matsouaka RA,et al. Heart failure with preserved,borderline,and reduced ejection fraction:5-year outcomes[J]. J Am Coll Cardiol,2017,70(20):2476-2486.

[10]Hao G,Wang X,Chen Z,et al. Prevalence of heart failure and left ventricular dysfunction in China:the China Hypertension Survey,2012-2015[J]. Eur J Heart Fail,2019,21(11):1329-1337.

[11]Lyu S,Yu L,Tan H,et al. Clinical characteristics and prognosis of heart failure with mid-range ejection fraction:insights from a multi-centre registry study in China[J]. BMC Cardiovasc Disord,2019,19(1):209-221.

[12]Solomon SD,Anavekar N,Skali H,et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients[J]. Circulation,2005,112(24):3738-3744.

[13]Rickenbacher P,Kaufmann BA,Maeder MT,et al. Heart failure with mid-range ejection fraction:a distinct clinical entity?Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)[J]. Eur J Heart Fail,2017,19(12):1586-1596.

[14]Moliner P,Lupón J,Barallat J,et al. Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction[J]. Int J Cardiol,2018,257:188-192.

[15]Tromp J,Khan MAF,Mentz RJ,et al. Biomarker profiles of acute heart failure patients with a mid-range ejection fraction[J]. JACC Heart Fail,2017,5(7):507-517.

[16]Zhao H,Shui B,Zhao Q,et al. Quantitative metabolomics reveals heart failure with midrange ejection fraction as a distinct phenotype of heart failure[J]. Can J Cardiol,2021,37(2):300-309.

[17]Wang B,Zhang L,Hu S,et al. β-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction[J]. Eur Heart J Cardiovasc Pharmacother,2021,pvab029.DOI:10.1093/ehjcvp/pvab029.Epub ahead of print.

[18]Lund LH,Claggett B,Liu J,et al. Heart failure with mid-range ejection fraction in CHARM :characteristics,outcomes and effect of candesartan across the entire ejection fraction spectrum[J]. Eur J Heart Fail,2018,20(8):1230-1239.

[19]Massie BM,Carson PE,McMurray JJ,et al. Irbesartan in patients with heart failure and preserved ejection fraction[J]. N Engl J Med,2008,359(23):2456-2467.

[20]Pitt B,Pfeffer MA,Assmann SF,et al. Spironolactone for heart failure with preserved ejection fraction[J]. N Engl J Med,2014,370(15):1383-1392.

[21]Vaduganathan M,Claggett BL,Jhund PS,et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction:a comparative analysis of three randomised controlled trials[J]. Lancet,2020,396(10244):121-128.

[22]Solomon SD,Rizkala AR,Lefkowitz MP,et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial[J]. Cir Heart Fail,2018,11(7):e004962.

[23]Wachter R,Shah SJ,Cowie MR,et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade:design and rationale of the PARALLAX trial[J]. ESC Heart Failure,2020,7(3):856-864.

[24]Brunner HP,Linssen GC,Smeele FJ,et al. Contemporary drug treatment of chronic heart failure with reduced ejection fraction:the CHECK-HF registry[J]. JACC Heart Fail,2019,7(1):13-21.

[25]Seferovic PM,Ponikowski P,Anker SD,et al. Clinical practice update on heart failure 2019:pharmacotherapy, procedures,devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail,2019,21(10):1169-1186.

[26]Gu J,Yin ZF,Zhang HL,et al. Characteristics and outcomes of transitions among heart failure categories:a prospective observational cohort study[J]. ESC Heart Fail,2020,7(2):616-625.

[27]Webb J,Draper J,Fovargue L,et al. Is heart failure with mid range ejection fraction (HFmrEF) a distinct clinical entity or an overlap group?[J]. Int J cardiol Heart Vasc,2018,21:1-6.

[28]Brann A,Janvanishstaporn S,Greenberg B. Association of prior left ventricular ejection fraction with clinical outcomes in patients with heart failure with midrange ejection fraction[J]. JAMA Cardiol,2020,5(9):1027-1035.

[29]Farré N,Lupon J,Roig E,et al. Clinical characteristics,one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction:a multicentre prospective observational study in Catalonia (Spain)[J]. BMJ Open,2017,7(12):e018719.

[30]Tsukamoto K,Suzuki A,Shiga T,et al. Changes in the left ventricular ejection fraction and outcomes in hospitalized heart failure patients with mid-range ejection fraction:a prospective observational study[J]. Intern Med,2021,60(10):1509-1518.

[31]Rastogi A,Novak E,Platts AE,et al. Epidemiology,pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction[J]. Eur J Heart Fail,2017,19(12):1597-1605.

[32]Li Q,Qiao Y,Tang J,et al. Frequency,predictors,and prognosis of heart failure with improved left ventricular ejection fraction:a single-centre retrospective observational cohort study[J]. ESC Heart Fail,2021,8(4):2755-2764.

[33]Basuray A,French B,Ky B,et al. Heart failure with recovered ejection fraction:clinical description,biomarkers, and outcomes[J]. Circulation,2014,129(23):2380-2387.

[34]Nadruz W Jr,West E,Santos M,et al. Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes[J]. Circ Heart Fail,2016,9(4):e002826.

[35]Tsuji K,Sakata Y,Nochioka K,et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study[J]. Eur J Heart Fail,2017,19(10):1258-1269.

[36]Wilcox JE,Fang JC,Margulies KB,et al. Heart failure with recovered left ventricular ejection fraction:JACC scientific expert panel[J]. J Am Coll Cardiol,2020,76(6):719-734.

[37]Abraham WT,Fonarow GC,Albert NM,et al. Predictors of in-hospital mortality in patients hospitalized for heart failure:insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)[J]. J Am Coll Cardiol,2008,52(5):347-356.

[38]Ponikowski P,Voors AA,Anker SD,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail,2016,18(8):891-975.

[39]Atherton JJ,Sindone A,Pasquale CG,et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand:Guidelines for the Prevention,Detection,and Management of Heart Failure in Australia 2018[J]. Heart Lung Circ,2018,27(10):1123-1208.

相似文献/References:

[1]刘春秋 熊双 刘剑刚 董国菊.射血分数保留性心力衰竭的诊断的研究进展[J].心血管病学进展,2021,(9):784.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
　LIU Chunqiu,XIONG Shuang,LIU Jiangang,et al.Diagnosis of Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2021,(2):784.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]

更新日期/Last Update: 2022-08-19